Immunogenicity and Reactogenicity of Alternative Schedules of Gardasil

April 12, 2017 updated by: PATH

Comparison of the Immunogenicity and Reactogenicity of Alternative Schedules of Gardasil Vaccine to Prevent HPV Infection

To demonstrate that Gardasil® vaccine, when given to girls 11-13 years of age according to 1 of 3 alternative 3-dose schedules (0, 3, 9 months; 0, 6, 12 months; or 0, 12, 24 months), results in anti-HPV type 16 and anti-HPV type 18 responses 28 days post-dose 3 that are similar to those obtained when the vaccine is given on the standard 3-dose schedule of 0, 2, 6 months.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

OBJECTIVES:

Primary objective:

To test the hypothesis that Gardasil® vaccine, when administered to girls 11-13 years of age according to 1 of 3 alternative 3-dose schedules (0,3,9 months; 0,6,12 months; or 0,12,24 months), results in anti-HPV 16 and anti-HPV 18 responses 28 days post-dose 3 that are similar to those obtained when the vaccine is administered on the standard 3-dose schedule of 0,2,6 months.

Secondary objectives:

  1. To test the hypothesis that Gardasil® vaccine, when administered to girls 11-13 years of age according to 1 of 3 alternative 3-dose schedules (0,3,9 months; 0,6,12 months; or 0,12,24 months), results in anti-HPV 6 and anti-HPV 11 responses 28 days post-dose 3 that are similar to those obtained when the vaccine is administered on the standard 3-dose schedule of 0,2,6 months.

  2. To describe the safety profile of the administration of Gardasil® according to each of the four schedules by assessing:

    (i) immediate reactogenicity (reactions within 30 minutes after each injection); (ii) solicited (local reactogenicity and fever) and unsolicited events occurring during the first 7 days following each vaccination; (iii) serious adverse events occurring up to one month following the last dose of vaccine; (iv) deaths or adverse events occurring at any time determined to be vaccination-related.

Study Type

Interventional

Enrollment (Actual)

903

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Vietnam
      • Hanoi, Vietnam
        • National Institute of Hygiene and Epidemiology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

11 years to 13 years (Child)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  1. 11-13 years of age.
  2. Signed informed consent form (both parent's & daughter's signature).
  3. Good health status.
  4. Able to comply with trial protocol.
  5. Plans to stay at current school for duration of study.

Exclusion Criteria:

  1. Prior HPV vaccination
  2. Pregnant or lactating or intends to become pregnant during study period.
  3. Apparent moderate or severe acute illness.
  4. Clinical history of bleeding disorder such as hemophilia, thrombocytopenia, or anticoagulant therapy.
  5. Clinical history of impaired immune responsiveness, whether due to use of immunosuppressive therapy, a genetic defect, HIV infection, or other causes.
  6. Hypersensitivity to the active substances or to any of the excipients of the HPV vaccine, or such reactions to other vaccines received in the past.
  7. Investigational drug or investigational vaccine administered during the period from 30 days before to 30 days after any dose of HPV vaccine.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: 0,2,6 month vaccination schedule
Biological: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
Three doses of quadrivalent HPV recombinant vaccine administered at different dosing intervals in each of four study arms.
Active Comparator: 0,3,9 month vaccination schedule
Biological: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
Three doses of quadrivalent HPV recombinant vaccine administered at different dosing intervals in each of four study arms.
Active Comparator: 0,6,12 month vaccination schedule
Biological: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
Three doses of quadrivalent HPV recombinant vaccine administered at different dosing intervals in each of four study arms.
Active Comparator: 0,12,24 month vaccination schedule
Biological: Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine
Three doses of quadrivalent HPV recombinant vaccine administered at different dosing intervals in each of four study arms.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Comparison of Antibody Response to HPV Type 16 1 Month Post-dose 3 for Each Alternative Schedule Compared to the Standard Schedule.
Time Frame: 25 months
25 months
Comparison of Antibody Response to HPV Type 18 1 Month Post-dose 3 for Each Alternative Schedule Compared to the Standard Schedule.
Time Frame: 25 months
25 months

Secondary Outcome Measures

Outcome Measure
Time Frame
Comparison of Antibody Response to HPV Type 6 1 Month Post-dose 3 for Each Alternative Schedule Compared to the Standard Schedule.
Time Frame: 25 months
25 months
Comparison of Antibody Response to HPV Type 11 1 Month Post-dose 3 for Each Alternative Schedule Compared to the Standard Schedule.
Time Frame: 25 months
25 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

PATH

Collaborators

National Institute of Hygiene and Epidemiology, Vietnam

Investigators

  • Principal Investigator: Kathy Neuzil, MD, MPH, PATH

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2007

Primary Completion (Actual)

January 1, 2010

Study Completion (Actual)

January 1, 2010

Study Registration Dates

First Submitted

August 31, 2007

First Submitted That Met QC Criteria

September 4, 2007

First Posted (Estimate)

September 5, 2007

Study Record Updates

Last Update Posted (Actual)

April 14, 2017

Last Update Submitted That Met QC Criteria

April 12, 2017

Last Verified

July 1, 2012

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • HPV01

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dose Schedule Study

Clinical Trials on Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe